Rachel King, CEO of GlycoMimetics, had a deep passion on biotechnology that made a huge impact on the biotech industry. King has hold many positions throughout her career, which made her influential in the industry. Her love for biotech lead her to become one of the nation’s leading figure in biotechnology. Due to this, King uses her passion for biotech to develop a lead drug for vaso occlusive crisis of sickle cell disease with the help of her company.
Before founding GlycoMimetics, King first studied at Dartmouth College, where she received her B.A. degree, and after that, she went to Harvard Business School in order to receive her M.B.A. degree. After receiving both degrees, she worked at Bain and Company in Boston, and at ALZA Corporation
…show more content…
Around three years later, she joined Novartis
Corporation as its senior vice president for two years, and as an entrepreneur in residence at New
Enterprise Association for another two years. She then joined the boards of BIO and MdBIO and was appointed to the state Life Sciences Advisory Board. Finally, in 2003, King cofounded
GlycoMimetics, a Gaithersburg MDbased company that is working on a lead drug that can cure sickle cell diseases.
Martinez 2
GlycoMimetics serves as a biotech company based in Gaithersburg, Maryland, where the company engages in designing and developing small molecule therapeutics to mimic the functions of bioactive carbohydrates. One of the company’s lead products is the GMI1070
Rivipansel Sodium, which is a potential treatment for vaso occlusive crisis, a condition that occurs with Sickle Cell crisis. Other products include the GMI1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.
While serving as CEO of GlycoMimetics, King served as a national voice on policy issues affecting the biotech industry, and has been involved with BIO (Biotechnology
…show more content…
She even testified before the Senate Committee on Small Business and
Entrepreneurship where she reinforced the need for patent protection incentives to encourage small business innovation. Her knowledge in biotech and leadership in BIO had made an outstanding influence to everyone who was involved in BIO with her.
Rachel King’s dedication and support in the biotech industry is what made her influential in the industry. In an article in BIOWorld, King states that biotech “is not “just another business, ” but a way to make a meaningful difference in people’s lives.” What she meant is that biotech has a more significant role to play in people’s lives than just being another occupation of someone.
GlycoMimetics teamed up with Pfizer by finding data for the GMI1070, and moved on to
Phase 2 in curing sickle cell disease. In a press release, Rachel King said that they “continue to make significant progress with our pipeline programs.” In addition to this, she said that the data,
“provide additional support for testing the drug candidate in sickle cell crisis.” What King said in
Martinez 3 the press release is that Pfizer is helping out GlycoMimetics by finding data of the